Form 4: Atlassian Co-Founder Michael Cannon-Brookes Sells Over 7,600 Shares Under Pre-Arranged Trading Plan
Insider Trading Report
Atlassian Co-Founder and CEO Michael Cannon-Brookes sold 7,665 shares of Class A Common Stock for approximately $1.59 million on July 1, 2025, as part of a pre-established Rule 10b5-1 trading plan.
Summary
- Michael Cannon-Brookes, Atlassian's Co-Founder, CEO, Director, and 10% Owner, sold a total of 7,665 shares of Class A Common Stock on July 1, 2025.
- The sales were executed at weighted-average prices ranging from $203.355 to $209.6395 per share.
- The total value of the shares sold is approximately $1,588,870.
- These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted by Mr. Cannon-Brookes on February 20, 2025.
- Following these transactions, Mr. Cannon-Brookes beneficially owns 482,895 shares of Class A Common Stock indirectly through CBC Co Pty Limited as trustee for the Cannon-Brookes Head Trust.
Sentiment
Score: 5
Explanation: The sentiment is neutral. While an insider sale could be seen negatively, the fact that it was executed under a pre-arranged 10b5-1 plan mitigates concerns about its implications for the company's immediate prospects. It represents a planned liquidity event for the insider.
Positives
- The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a structured and non-discretionary sale rather than a reaction to immediate market conditions.
Negatives
- A significant insider sale, even if planned, can sometimes be perceived negatively by investors as it reduces the insider's direct stake in the company.
Risks
- No specific risks related to the company's operations or financial health are mentioned in this Form 4 filing. The only inherent risk is the perception of insider selling.
Future Outlook
This Form 4 filing does not contain any forward-looking statements or guidance regarding Atlassian's future performance or strategic outlook.
Industry Context
This Form 4 filing reports an individual insider stock transaction and does not provide information relevant to broader industry trends or competitive landscape analysis for the software or collaboration tools industry.
Comparison to Industry Standards
- This document is a standard insider trading report (Form 4) and does not contain information that allows for a comparison to industry-wide financial or operational benchmarks. It details a personal stock transaction by an executive, not company performance metrics.
Related Party Transactions
- Shares are held indirectly by CBC Co Pty Limited as trustee for the Cannon-Brookes Head Trust, indicating a transaction involving a trust associated with the reporting person.
Stakeholder Impact
- Shareholders: The sale by a co-founder and CEO could lead to minor concerns about insider confidence, though the 10b5-1 plan mitigates this. The reduction in direct beneficial ownership by a key executive is noted.
- Employees, Customers, Suppliers, Creditors: No direct impact on these stakeholders is indicated by this insider trading report.
Next Steps
- The document does not specify any future actions, events, or milestones for the company or the reporting person beyond the execution of the existing 10b5-1 plan.
Key Dates
| Date | Description |
|---|---|
| February 20, 2025 | Date Rule 10b5-1 trading plan was adopted by Michael Cannon-Brookes. |
| July 1, 2025 | Date of stock transactions (sales) by Michael Cannon-Brookes. |
| July 2, 2025 | Date the Form 4 was signed and filed. |
Recommendation
holdKeywords
Atlassian, TEAM, Michael Cannon-Brookes, Insider Sale, Form 4, SEC Filing, Stock Transaction, 10b5-1 Plan, Class A Common Stock, Corporate Governance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.